Market research
EZ1.F Enzon Pharmaceuticals, Inc
F EUR Not available
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.27
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- US2939041081
- Market cap
- 9M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.27
About
About Enzon Pharmaceuticals, Inc
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EZ1.F discussion.
5 years, 5 months ago
Enzon Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 53.6% above its 200 day moving average.
From a valuation standpoint, the stock is 40.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 783.6.
Enzon Pharmaceuticals, Inc's total revenue sank by 30.6% to $34K since the same quarter in the previous year.
Its net income has dropped by 62.6% to $-426K since the same quarter in the previous year.
Finally, its free cash flow fell by 174.0% to $-545K since the same quarter in the previous year.
Based on the above factors, Enzon Pharmaceuticals, Inc gets an overall score of 2/5.